EUVIMEDEUVIMED entdecken
Crossref

Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non–Small-Cell Lung Cancer

Jessica Donington, Xiaohan Hu, Su Zhang, Yan Song, Ashwini Arunachalam, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch, Ayman Samkari

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.03.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Jessica Donington und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Section Thoracic Surgery, University of Chicago, Chicago, USA. Electronic address: jdonington@surgery.bsd.uchicago.edu. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Novel neoadjuvant chemoimmunotherapy treatments are being investigated for locally advanced non-small-cell lung cancer (NSCLC), but real-world outcomes for neoadjuvant treatments are poorly understood. This study examined neoadjuvant treatment patterns, real-world event-free survival (rwEFS) and overall survival (OS) in patients with resected, stage II-III NSCLC in the United States (US). METHODS: This retrospective study identified patients in the SEER-Medicare database (2007-2019) with newly diagnosed stage II, IIIA, and IIIB (N2) NSCLC (AJCC 8th edition) treated with neoadjuvant chemo/chemoradiotherapy and resection (index date: neoadjuvant therapy initiation). Neoadjuvant treatment regimens were described. rwEFS (time from index to first recurrence or death, whichever occurred first) and OS (time from index to death) were summarized by Kaplan-Meier analysis for overall population, by disease stage at diagnosis, and by neoadjuvant treatment modality. RESULTS: 221 patients (stage II, N=70; stage III, N=151) met eligibility criteria. The median follow-up from index was 32.7 months. All patients received neoadjuvant chemotherapy (51%) or chemoradiotherapy (49%) prior to surgery; 97% of patients received platinum-based regimens, among which carboplatin+paclitaxel was the most frequent (45%). In all patients, median rwEFS was 17.6 months and 5-year rwEFS was 20.9%; median OS was 48.5 months and 5-year OS was 44.9%. 71% of patients had disease recurrence during follow-up; among them, 28% developed locoregional recurrence as the first recurrence event. CONCLUSIONS: Patients with resected, stage II-III NSCLC who received neoadjuvant chemo/chemoradiotherapy have high rates of disease recurrence and poor survival outcomes, highlighting need for more effective treatments to improve survival rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsLung NeoplasmsCarcinoma, Non-Small-Cell LungNeoplasm Recurrence, LocalNeoadjuvant TherapyRetrospective StudiesChemoradiotherapy, AdjuvantNeoplasm StagingTreatment OutcomeKaplan-Meier EstimatePneumonectomyFollow-Up StudiesSurvival RateHumansMaleFemaleAgedSEER ProgramMedicareUnited States

Stichwörter der Autor:innen

NSCLCOverall survivalReal-world event-free survivalRecurrence

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Surgery, Section Thoracic Surgery, University of Chicago, Chicago, USA. Electronic address: jdonington@surgery.bsd.uchicago.edu.
  • Merck & Co., Inc., Rahway, NJ.
  • Analysis Group, Inc., Boston, MA.

Zitieren

APA

Donington, J., Hu, X., Zhang, S., Song, Y., Arunachalam, A., Chirovsky, D., Gao, C., Lerner, A., Jiang, A., Signorovitch, J., & Samkari, A. (2024). Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non–Small-Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.03.006

Vancouver

Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, et al. Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.03.006

BibTeX
@article{Donington2024,
  author = {Donington, Jessica and Hu, Xiaohan and Zhang, Su and Song, Yan and Arunachalam, Ashwini and Chirovsky, Diana and Gao, Chi and Lerner, Ari and Jiang, Anya and Signorovitch, James and Samkari, Ayman},
  title = {Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non–Small-Cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.03.006}
}
Kostenlos starten →